Table 7.

Prevalence of CKD Stages 1–4: Non-Sex-Specific Albumin-Creatinine Ratio Cut Points: MDRD Study vs. Mayo vs. Cockcroft-Gault Estimating Equations

	Estimating Equation
	MDRD Study			Mayo				Cockcroft-Gault
CKD Stage	Prevalence %*	95% CI	Population n†	Prevalence %*	95% CI	Population n†	Prevalence Ratio‡	Prevalence %*	95% CI	Population n†	Prevalence Ratio§
1	2.12	1.93–2.32	4,607,171	2.64	2.38–2.93	5,737,232	1.25	1.91	1.70–2.13	4,150,800	0.90
2	3.28	2.97–3.62	7,128,076	2.72	2.41–3.06	5,991,087	0.83	2.65	2.37–2.95	5,758,964	0.81
3	8.00	7.33–8.74	17,385,550	5.80	5.32–6.31	12,604,524	0.73	17.39	16.52–18.28	37,791,840	2.17
4	0.35	0.27–0.47	760,618	0.53	0.41–0.68	1,151,793	1.51	1.16	0.97–1.38	2,520,905	3.33
1–4	13.75	12.99–14.54	29,881,414	11.68	11.04–12.34	25,832,903	0.85	23.10	22.07–24.16	50,200,776	1.67
3–4	8.36	7.68–9.09	18,167,900	6.32	5.82–6.87	13,734,585	0.76	18.55	17.60–19.53	40,312,745	2.22

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease.

^*Prevalence estimates of stage 1 and stage 2 incorporate persistence estimates for microalbuminuria of 50.9% if estimated glomerular filtration rate ≥ 90 mL/min/1.73 m² (≥ 1.50 mL/s/1.73 m²) and 75.0% if 60–89 mL/min/1.73 m² (1.00–1.48 mL/s/1.73 m²).

^†Population n based on the estimated 2006 US population aged 20 years and older: 217,319,378.

^‡Mayo:MDRD

^§Cockcroft-Gault:MDRD